FIELD: medicine.
SUBSTANCE: what is presented is the reassortant A/17/New Caledonia/99/76(H1N1) vaccine strain of influenza A virus. Said strains replicates actively in growing chicken embryos at optimum temperature 33°C; it is characterised by thermal sensitivity, cold adaptation and attenuation for laboratory animals. The reassortant has inherited the genes coding surface glycoproteins - hemagglutinin and neuraminidase from an epidemic type A(H1N1) virus, and and six genes coding non-glycosylated proteins from the attenuation donor A/Moscow/21/17/65(H2N2). Thereby the A/17/New Caledonia/99/76(H1N1) vaccine strain has such genome formula and biological properties to meet the requirements for the vaccine strains for live influenza vaccines according to the Manufacturer's Monograph 42-0417.
EFFECT: invention may be used in public health service for prevention of influenza infection caused by the epidemic influenza virus strain.
4 tbl, 2 ex
Authors
Dates
2012-10-20—Published
2011-06-16—Filed